Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesAxsome Therapeutics Inc

Axsome Therapeutics Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
132.76 USD 0.39 ( 0.29%)
Last update at 2026-11-09T17:55:00Z
VOLUME
304188
Market Cap
9652.11M

Momentum Score

…

Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist, sigma-1 receptor agonist, aminoketone, and CYP2D6 inhibitor indicated for the treatment of major depressive disorder in adults; Sunosi (solriamfetol), a dopamine and norepinephrine reuptake inhibitor, trace amine-associated receptor 1 agonist, and 5-HT1A agonist indicated for the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea; and Symbravo (MoSEIC meloxicam rizatriptan), or AXS-07, a rapidly absorbed, multi-mechanistic, selective COX-2 inhibitor, and 5-HT1B/1D agonist indicated for the acute treatment of migraine with or without aura. It also develops AXS-05 (dextromethorphan-bupropion), an investigational N-methyl-D-aspartate receptor antagonist, which has completed Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-12 (reboxetine), a highly selective and potent norepinephrine reuptake inhibitor and cortical dopamine modulator, which has completed Phase II trial to treat narcolepsy; AXS-14 (esreboxetine), a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and Solriamfetol, a dopamine and norepinephrine reuptake inhibitor, which is in Phase III trial for treating attention deficit hyperactivity, major depressive, binge eating, and excessive sleepiness associated with shift work disorder. It has a research collaboration agreement with Duke University for evaluating AXS-05 in a Phase 2 clinical trial in smoking cessation treatment. The company was incorporated in 2012 and is based in New York, New York.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
131.41
Low
134.71
High
52 Week Price Range
96.09
Low
191.50
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Axsome Therapeutics is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for central nervous system disorders, with its lead approved medication Auvelity for major depressive disorder. Long-term growth may be driven by U.S. uptake of Auvelity, potential label expansions and approvals from its CNS pipeline, and improved market access that could support revenue diversification.
Material investment risks include dependence on a single recently launched product for revenue, execution and reimbursement pressures in competitive CNS markets, and clinical/regulatory outcomes for pipeline candidates that could necessitate additional financing.

Risk Score
Medium

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
132.37
Dividend Yield
-
Revenue TTM
638.50M
Revenue Per Share
12.84
Gross Profit TTM
591.02M
Debt / Equity
2.73
ROE
-252.12%
Net Debt
-81.64M
ROCE
-56.97%
Diluted EPS TTM
-3.68

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -183.70M -287.13M -238.28M -187.13M -130.40M
Net income -183.17M -287.22M -239.24M -197.77M -134.94M
Selling general administrative 570.60M 310.16M 222.82M 159.25M 66.65M
Selling and marketing expenses - 101.20M 100.30M - -
Gross profit 591.02M 352.39M 244.53M 44.84M -
Reconciled depreciation 9.06M 7.96M 6.83M 4.14M 1.16M
Ebit -177.15M -280.56M -231.82M -176.50M -125.86M
Ebitda -168.08M -272.60M -224.99M -170.94M -124.71M
Depreciation and amortization 9.06M 7.96M 6.83M 5.56M 1.16M
Non operating income net other - - - - -5.70M
Operating income -169.24M -280.56M -231.82M -176.50M -124.71M
Other operating expenses 807.73M 666.25M 502.43M 226.54M 124.71M
Interest expense 6.56M 6.57M 6.45M 7.33M 5.70M
Tax provision -0.53M 0.09M 0.96M - -
Net interest income -6.56M -6.57M -6.45M -7.33M -5.70M
Income tax expense -0.53M 0.09M 0.96M 10.63M 4.54M
Total revenue 638.50M 385.69M 270.60M 50.04M 0.00M
Total operating expenses 760.25M 632.95M 476.36M 221.34M 124.71M
Cost of revenue 47.48M 33.30M 26.07M 5.20M -
Total other income expense net -14.47M -6.57M -6.45M -10.63M -5.70M
Net income from continuing ops -183.17M -287.22M -239.24M -187.13M -130.40M
Net income applicable to common shares - - - -187.13M -130.40M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 689.80M 568.50M 588.24M 331.48M -338.36M
Intangible assets 40.52M 46.89M 53.29M 59.66M -
Other current assets 13.65M 11.98M 8.12M 2.78M 0.05M
Total liab 601.51M 511.48M 397.26M 221.92M 70.84M
Total stockholder equity 88.30M 57.02M 190.98M 109.56M -409.20M
Other current liab 240.32M 157.15M 96.91M 57.53M 9.30M
Common stock 0.01M 0.01M 0.01M 0.00M 0.00M
Capital stock 0.01M 0.01M 0.01M 0.00M 0.00M
Retained earnings -1305.96M -1122.79M -835.57M -596.33M -409.20M
Other liab - - - 31.10M -
Good will 12.04M 12.04M 12.04M 10.31M -
Other assets - - - 14.72M -426.14M
Cash 322.93M 315.35M 386.19M 200.84M 86.47M
Total current liabilities 378.84M 230.10M 138.85M 96.56M 23.07M
Net debt -81.64M -122.40M -199.82M -106.16M -36.76M
Short term debt 72.98M 1.83M 1.27M 0.42M 0.62M
Short long term debt 70.00M - - - -
Short long term debt total 241.29M 192.96M 186.37M 94.68M 49.71M
Other stockholder equity 1394.25M 1179.80M 1026.54M 705.88M -0.00M
Property plant equipment - - - 1.14M 0.28M
Total current assets 588.99M 485.06M 504.26M 245.64M 86.52M
Net tangible assets - - - 39.59M 15.63M
Net receivables 224.46M 142.00M 94.82M 37.70M -
Long term debt 117.75M 180.71M 178.07M 94.26M 49.09M
Inventory 27.94M 15.73M 15.13M 4.32M -
Accounts payable 65.54M 72.00M 40.68M 38.61M 13.15M
Accumulated other comprehensive income - - 0.00M - -
Common stock total equity - - - - 0.00M
Retained earnings total equity - - - - -409.20M
Non currrent assets other 27.40M 19.11M 11.03M 14.72M 0.32M
Non current assets total 100.82M 83.43M 83.97M 85.83M 1.27M
Capital lease obligations 30.37M 12.24M 8.30M 0.42M 0.62M
Long term debt total - - - - 49.09M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - -0.27M -0.58M -53.70M -0.31M
Change to liabilities - - - 25.46M 0.23M
Total cashflows from investing activities -0.48M -0.27M -0.58M -53.70M -0.31M
Net borrowings -4.11M -0.99M 85.00M 45.00M -0.31M
Total cash from financing activities 101.47M 57.84M 331.01M 284.58M 11.13M
Change to operating activities - - - 37.24M 0.68M
Net income -183.17M -287.22M -239.24M -187.13M -130.40M
Change in cash 7.58M -70.84M 185.35M 114.37M -97.40M
Begin period cash flow 315.35M 386.19M 200.84M 86.47M 183.88M
End period cash flow 322.93M 315.35M 386.19M 200.84M 86.47M
Total cash from operating activities -93.41M -128.41M -145.08M -116.51M -108.23M
Issuance of capital stock 67.90M 40.78M 258.75M 236.79M 7.21M
Depreciation 9.06M 7.96M 6.83M 5.56M 1.16M
Other cashflows from investing activities -0.48M -0.27M - - -
Change to inventory -15.67M 0.74M -8.16M -5.28M -1.33M
Change to account receivables -82.46M -47.18M -57.12M -37.70M -37.70M
Sale purchase of stock - - -1.83M - 11.61M
Other cashflows from financing activities -17.05M 18.05M -12.74M 47.79M 3.92M
Change to netincome - - - 39.91M 20.80M
Capital expenditures 0.48M 0.27M 0.58M 0.70M 0.31M
Cash flows other operating - - - - -0.00M
Cash and cash equivalents changes - - - - -97.40M
Change in working capital -22.52M 33.90M -28.39M 23.67M 0.32M
Stock based compensation 93.75M 85.22M 62.62M 37.73M 20.80M
Other non cash items 9.48M 116.95M 53.10M 3.66M -0.10M
Free cash flow -93.89M -128.68M -145.66M -117.21M -108.53M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
AXSM
Axsome Therapeutics Inc		 0.39
0.29%		 132.76 - 333.33 15.12 109.49 14.98 -14.81
NVO
Novo Nordisk A/S		 1.09
2.72%		 41.41 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 1.49
0.27%		 548.58 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 18.16
2.01%		 922.51 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Axsome Therapeutics Inc

Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist, sigma-1 receptor agonist, aminoketone, and CYP2D6 inhibitor indicated for the treatment of major depressive disorder in adults; Sunosi (solriamfetol), a dopamine and norepinephrine reuptake inhibitor, trace amine-associated receptor 1 agonist, and 5-HT1A agonist indicated for the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea; and Symbravo (MoSEIC meloxicam rizatriptan), or AXS-07, a rapidly absorbed, multi-mechanistic, selective COX-2 inhibitor, and 5-HT1B/1D agonist indicated for the acute treatment of migraine with or without aura. It also develops AXS-05 (dextromethorphan-bupropion), an investigational N-methyl-D-aspartate receptor antagonist, which has completed Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-12 (reboxetine), a highly selective and potent norepinephrine reuptake inhibitor and cortical dopamine modulator, which has completed Phase II trial to treat narcolepsy; AXS-14 (esreboxetine), a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and Solriamfetol, a dopamine and norepinephrine reuptake inhibitor, which is in Phase III trial for treating attention deficit hyperactivity, major depressive, binge eating, and excessive sleepiness associated with shift work disorder. It has a research collaboration agreement with Duke University for evaluating AXS-05 in a Phase 2 clinical trial in smoking cessation treatment. The company was incorporated in 2012 and is based in New York, New York.

One World Trade Center, New York, NY, United States, 10007

212 332 3241

https://www.axsome.com

925

Name Title Year Born
Dr. Herriot Tabuteau M.D. Founder, Chairman, CEO & Pres 1968
Mr. Nick Pizzie CPA, M.B.A. Chief Financial Officer 1975
Mr. Mark L. Jacobson COO & Sec. 1983
Mr. Hunter Murdock Esq. Exec. VP of Legal & Compliance NA
Dr. Amanda Jones Pharm.D. Sr. VP of Clinical Devel. 1983
Ms. Lori Englebert M.B.A. Exec. VP of Commercial & Bus. Devel. 1978
Mr. Kevin Laliberte Pharm.D. Exec. VP of Product Strategy 1978
Joseph Debrah-Afful CPA, M.B.A. Director of Fin. NA
Dr. Herriot Tabuteau M.D. Founder, Chairman, CEO & President 1968
Mr. Mark L. Jacobson COO & Secretary 1983

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

GFR
CAD 10.94
+37.96%
MOON
CAD 4.90
+11.11%
UCU
CAD 2.37
+10.75%
ANRG
CAD 1.90
+10.47%
EPRX
CAD 10.71
+10.30%
DIV
CAD 3.77
-7.37%
CSU
CAD 3281.97
-6.93%
LMN
CAD 26.62
-5.23%
TOI
CAD 99.75
-4.80%
GRZ
CAD 5.05
-4.72%

Equity Sectors*

  • Basic Materials

    +5.01%

  • Communication Services

    -0.62%

  • Consumer Cyclical

    +1.25%

  • Consumer Defensive

    +0.10%

  • Energy

    +1.86%

  • Financial Services

    +1.87%

  • Healthcare

    +1.14%

  • Industrials

    +3.75%

  • Real Estate

    +0.53%

  • Technology

    +2.31%

  • Utilities

    +0.99%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…